Afatinib is used to treat non-small cell lung cancer (NSCLC) that is metastatic (spread to other parts of your body besides your lungs), and has abnormal epidermal growth factor (EGF) receptor genes. These abnormal genes promote the growth of cancer cells.
Medicince introduction including background, function, caution, etc.
Indication For the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with Epidermal Growth factor Receptor EGFR mutation.
For the treatment of locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum based chemotherapy.
SideEffects Acne, nose bleed, runny nose, nausea/vomiting, or loss of appetite
Mechanism Of Action
Afatinib is a potent and selective, irreversible ErbB family blocker . Afatinib covalently binds to and irreversibly blocks signaling from all homo and heterodimers formed by the ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4